ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors ARTIDIS Announces Appointment of Dr. Ajit Singh, Ph.D. to Board of Directors Basel, Switzerland, February 13, 2023 – ARTIDIS AG, a clinical stage medical technology company on a mission to shift...

MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment HOUSTON and BASEL, Switzerland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- ARTIDIS AG, the developer of the first nanomechanical technology platform for tissue analytics, and The University of Texas MD...

ARTIDIS enters clinical collaboration to investigate nanomechanical profiling as a novel diagnostic and treatment optimization approach in patients with lung cancer Basel, Switzerland, May 4, 2021 – ARTIDIS AG, a privately held health-tech company, announces a collaboration with Hospital Clínic de Barcelona and the University of Barcelona to investigate the...

ARTIDIS investigates nanomechanical tissue signature to improve response to radio/immuno-therapy in lung cancer Basel, Switzerland, December 21, 2020 – ARTIDIS AG, a privately held health-tech company, investigates the predictive value of nanomechanical tissue signature on outcomes in response to cancer...

ARTIDIS First Prospective Study, "NANO”, Evaluating its Nanotechnology Platform Based on a Novel Nanomechanical Biomarker in Breast Cancer Meets Primary Endpoint Basel, Switzerland, June 22, 2020 - ARTIDIS AG, a clinical stage health-tech company, announced today that its proprietary nanotechnology platform for cancer diagnosis has met the primary endpoint in...